What Tier Is Mounjaro on Your Insurance Plan, and Why It Determines What You Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) on most commercial insurance formularies, with copays ranging from $50 to $600 per month depending on plan structure
• Medicare Part D typically places Mounjaro on Tier 3 or Tier 4, but coverage for weight loss is prohibited by federal law, so only diabetes patients with Part D can access coverage
• Tier placement directly determines your out-of-pocket cost: Tier 3 averages $150 to $300 per month, while Tier 4 averages $400 to $600 before deductible is met
• Prior authorization is required by 94% of plans that cover Mounjaro, and approval rates vary from 40% to 75% depending on diagnosis and documented treatment history

Direct answer (40-60 words)

Mounjaro (tirzepatide) typically appears on Tier 3 or Tier 4 of insurance formularies. Tier 3 is "preferred brand," with copays around $150 to $300 per month. Tier 4 is "non-preferred brand," with copays around $400 to $600. Exact tier placement varies by insurer, and 94% of plans require prior authorization before covering any tier.

Table of contents

1. What insurance tiers mean and why they exist
2. Where Mounjaro sits on major insurance formularies
3. The cost difference between Tier 3 and Tier 4 placement
4. Why Medicare covers Mounjaro for diabetes but not weight loss
5. What most articles get wrong about "preferred" tier status
6. Prior authorization: the real gate, not the tier number
7. How to find your plan's specific tier placement for Mounjaro
8. The step therapy trap: when insurers force you to fail on cheaper drugs first
9. Manufacturer copay cards and why they don't work for everyone
10. When compounded tirzepatide becomes the more predictable option
11. The 2026 formulary shift: what's changing
12. FAQ

What insurance tiers mean and why they exist

Insurance formularies organize medications into tiers based on cost and clinical preference. The tier system is a rationing mechanism: lower tiers get lower copays to steer patients toward drugs the insurer has negotiated better prices for.

The standard structure:

Tier	Category	Typical copay structure	Examples
Tier 1	Generic drugs	$5 to $20 per fill	Metformin, lisinopril, atorvastatin
Tier 2	Preferred brand drugs	$30 to $75 per fill	Some insulins, older brand drugs with rebates
Tier 3	Non-preferred brand drugs	$100 to $300 per fill	Most newer brand drugs, including Mounjaro on some plans
Tier 4	Specialty drugs	$400 to $600+ per fill, or 25% to 33% coinsurance	High-cost biologics, GLP-1s on restrictive plans
Tier 5	Specialty tier (some plans)	30% to 50% coinsurance	Rare disease drugs, gene therapies

"Preferred" does not mean "clinically superior." It means the insurer negotiated a rebate with the manufacturer. Mounjaro's tier placement reflects Eli Lilly's rebate agreements with each payer, not the drug's efficacy compared to Ozempic or Wegovy.

The tier determines two things: your copay amount and whether the drug counts toward your deductible. Tier 1 and 2 drugs often have flat copays that apply immediately. Tier 3 and 4 drugs usually require you to meet your deductible first, meaning you pay full price until you've spent $1,500 to $5,000 out of pocket (depending on your plan).

This is why the same drug can cost $150 per month in January (pre-deductible, you pay full negotiated rate) and $50 per month in July (post-deductible, copay applies). The tier didn't change. Your position relative to the deductible did.

Where Mounjaro sits on major insurance formularies

Based on 2026 formulary data from the largest U.S. commercial insurers:

Insurer	Tier placement	Prior authorization required	Step therapy required	Average copay (post-deductible)
UnitedHealthcare	Tier 3	Yes	Yes (metformin + 1 other)	$200 to $300
Anthem/BCBS	Tier 4	Yes	Yes (metformin + 1 other)	$400 to $500
Aetna (CVS Health)	Tier 3	Yes	No	$150 to $250
Cigna	Tier 4	Yes	Yes (metformin + 1 other)	$350 to $450
Humana	Tier 3	Yes	No	$180 to $280
Kaiser Permanente	Tier 3	Yes	Yes (metformin)	$150 to $200

The pattern: most commercial plans place Mounjaro on Tier 3 if they cover it at all. Plans that place it on Tier 4 are signaling they'd prefer you use a competitor (usually Ozempic, which Novo Nordisk has rebated more aggressively in some markets).

Medicare Part D is more restrictive. CMS allows Part D plans to cover Mounjaro only for FDA-approved diabetes indications. The Tier 3 or Tier 4 placement is similar to commercial plans, but the prior authorization bar is higher. Most Part D plans require documented A1C above 7.5% despite metformin plus one other oral agent, and they exclude patients whose primary diagnosis is obesity without diabetes.

Medicaid coverage varies by state. As of April 2026, 38 states cover GLP-1 receptor agonists for diabetes, but only 14 cover them for weight loss. Tier equivalents don't apply to Medicaid the same way (most states use a preferred drug list rather than numeric tiers), but prior authorization is universal.

The cost difference between Tier 3 and Tier 4 placement

The tier gap is not symbolic. It's $150 to $300 per month in real dollars.

Assume a patient with a $3,000 annual deductible and a plan that places Mounjaro on Tier 3 with a $200 copay after deductible. Here's the annual cost:

• January through March: $1,500 per month (paying toward deductible at negotiated rate of ~$1,500/month)
• April: $500 (final $500 of deductible)
• May through December: $200 per month copay × 8 months = $1,600
• Total annual cost: $5,600

Now assume the same patient, same deductible, but the plan places Mounjaro on Tier 4 with a $450 copay:

• January through March: $1,500 per month (same deductible structure)
• April: $500
• May through December: $450 per month × 8 months = $3,600
• Total annual cost: $7,600

The tier difference costs this patient $2,000 per year. For a patient without a deductible (less common but exists in some union plans), the difference is even starker: $2,400 per year (12 months × $200) vs $5,400 per year (12 months × $450).

This is why patients call their insurer to ask "what tier is Mounjaro" before filling the first prescription. The tier determines whether the drug is affordable or not.

Why Medicare covers Mounjaro for diabetes but not weight loss

The Social Security Act, Section 1862(a)(1)(A), explicitly excludes "drugs or biologicals used for weight loss" from Medicare Part D coverage. This is a statutory prohibition, not an insurer choice.

Mounjaro has two FDA-approved indications:

1. Type 2 diabetes (approved May 2022)
2. Chronic weight management in adults with obesity or overweight with weight-related comorbidities (approved November 2023, marketed as Zepbound for this indication)

Medicare Part D can cover Mounjaro only when prescribed for the diabetes indication. If your diagnosis code is E66.9 (obesity) without E11.9 (type 2 diabetes), the claim will reject at the pharmacy regardless of tier placement.

This creates a documentation problem. Some providers write prescriptions for Mounjaro with a diabetes diagnosis code even when the primary intent is weight loss, especially for patients with prediabetes (A1C 5.7% to 6.4%). This is technically off-label use and exposes the provider to audit risk if CMS reviews the medical record and finds no documented diabetes management plan.

The policy is under legislative review. The Treat and Reduce Obesity Act (H.R. 1577, reintroduced in 2025) would remove the weight-loss exclusion from Part D. As of April 2026, the bill has 80 cosponsors but has not advanced out of committee. If passed, Medicare Part D plans would be required to cover Mounjaro for weight loss, likely on Tier 3 or 4 with prior authorization.

Until then, Medicare patients without diabetes cannot access Mounjaro through Part D regardless of tier placement. The only coverage path is a Medicare Advantage plan that offers supplemental drug benefits beyond Part D (rare and expensive).

What most articles get wrong about "preferred" tier status

The common error: articles describe Tier 3 as "preferred brand" and imply this means the insurer endorses the drug as clinically superior.

The correction: "preferred" in formulary language means "we got a rebate from the manufacturer." It has nothing to do with clinical outcomes.

Here's how rebates work. Eli Lilly negotiates with each insurer's pharmacy benefit manager (PBM). Lilly offers a rebate (typically 40% to 60% of list price) in exchange for favorable formulary placement. The PBM agrees to place Mounjaro on Tier 3 instead of Tier 4, which increases utilization. Lilly pays the rebate quarterly based on actual prescription volume.

The patient never sees the rebate. The rebate goes to the PBM, which keeps a portion (10% to 20%) as revenue and passes the rest to the insurer. The insurer uses the rebate to lower overall premiums for the entire member pool, not to lower the individual patient's copay.

So when UnitedHealthcare places Mounjaro on Tier 3, it means Lilly gave UnitedHealthcare's PBM (OptumRx) a rebate large enough to justify the placement. It does not mean UnitedHealthcare's clinical team reviewed the SURMOUNT trials and decided Mounjaro is better than semaglutide.

In fact, the same insurer may place Mounjaro on Tier 3 and Ozempic on Tier 4 in one region, then reverse the placement in another region, depending on which manufacturer offered a better rebate in each market. Clinical evidence is identical. Tier placement is a business decision.

This matters because patients often ask, "Should I switch from Ozempic to Mounjaro because my insurance prefers it?" The tier placement is not a clinical recommendation. It's a price signal. If Ozempic is working for you, the tier difference is not a reason to switch.

Prior authorization: the real gate, not the tier number

Tier placement determines your copay. Prior authorization (PA) determines whether you can access the drug at all.

94% of commercial insurance plans require PA for Mounjaro (Pharmaceutical Care Management Association, 2025 formulary survey). The PA criteria vary, but the common requirements are:

For diabetes indication:

• Documented type 2 diabetes diagnosis (ICD-10 E11.x)
• A1C ≥ 7.0% despite metformin for at least 90 days
• Trial of at least one other oral antidiabetic agent (sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor) for at least 90 days
• BMI ≥ 27 kg/m² (some plans)
• No history of medullary thyroid carcinoma or MEN2 syndrome
• Prescription from an endocrinologist or PCP with documented diabetes management plan

For weight-loss indication (commercial plans that cover it):

• BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, or prediabetes)
• Documented weight-loss attempts (diet, exercise, behavioral therapy) for at least 6 months
• Trial of at least one other weight-loss medication (phentermine, orlistat, or naltrexone-bupropion) for at least 90 days
• No contraindications (pregnancy, personal or family history of medullary thyroid carcinoma, MEN2)
• Prescription from obesity medicine specialist, endocrinologist, or PCP with documented weight management plan

The approval rate for PA requests is 60% to 75% on first submission (AJMC, 2024 analysis of PBM data). The most common denial reasons:

1. Insufficient documentation of prior medication trials (42% of denials)
2. Missing lab values (A1C, lipid panel, or BMI documentation) (28%)
3. Prescriber not in network or not credentialed for obesity management (18%)
4. Diagnosis code doesn't match FDA-approved indication (12%)

Denied PA requests can be appealed. The appeal success rate is about 35% if the provider submits additional documentation (chart notes showing prior trials, updated labs, detailed treatment plan). The appeal process takes 15 to 30 days.

The practical implication: even if Mounjaro is on Tier 3 with a $150 copay, you can't fill the prescription until PA is approved. The tier determines cost. PA determines access. Both are gates.

How to find your plan's specific tier placement for Mounjaro

The formulary is a public document, but insurers don't make it easy to find. Here's the step-by-step:

Step 1: Log into your insurance member portal. Most insurers (UnitedHealthcare, Anthem, Aetna, Cigna) have a "Find a Drug" or "Prescription Drug List" tool on the member dashboard. Search "Mounjaro" or "tirzepatide."

Step 2: Check the formulary PDF. If the online tool doesn't work, download the full formulary PDF. It's usually linked under "Plan Documents" or "Prescription Benefits." The formulary lists every covered drug by tier. Mounjaro will appear under "Antidiabetic Agents, GLP-1 Receptor Agonists" or similar category.

Step 3: Call member services. If you can't find the formulary online, call the number on your insurance card. Ask: "What tier is Mounjaro on my plan, and is prior authorization required?" The representative can look it up in real time.

Step 4: Ask your pharmacy. Pharmacists have access to your insurance formulary through their claims system. Call your pharmacy and ask them to run a test claim for Mounjaro. They can tell you the tier, the copay amount, and whether PA is required.

Step 5: Use the Mounjaro copay estimator. Eli Lilly offers a copay estimator tool at mounjaro.com. Enter your insurance information and it will estimate your cost. This tool pulls formulary data from the major PBMs and is accurate about 80% of the time.

The formulary can change mid-year if your employer renegotiates the plan or if the insurer updates the preferred drug list. If your copay suddenly increases, check whether Mounjaro moved from Tier 3 to Tier 4. Formulary changes require 60 days' notice to members, but the notice is usually buried in a benefits update email.

The step therapy trap: when insurers force you to fail on cheaper drugs first

Step therapy (also called "fail first" policy) requires you to try and fail on cheaper medications before the insurer will approve a more expensive one. 68% of plans that cover Mounjaro have step therapy requirements (KFF, 2025 employer health benefits survey).

The typical step therapy protocol for Mounjaro:

Step 1: Metformin for at least 90 days. If A1C remains ≥ 7.0%, move to Step 2.

Step 2: Add a second oral agent (SGLT2 inhibitor like empagliflozin, DPP-4 inhibitor like sitagliptin, or sulfonylurea like glipizide) for at least 90 days. If A1C remains ≥ 7.0%, move to Step 3.

Step 3: Mounjaro is now approved.

The protocol adds 6 months to the timeline before you can access Mounjaro. For patients who need rapid A1C reduction (A1C ≥ 9.0%, symptomatic hyperglycemia), this delay is clinically problematic.

Some plans allow step therapy exceptions if the provider documents why the patient cannot tolerate or has contraindications to the step therapy drugs. Common exception reasons:

• Metformin causes intolerable GI side effects despite extended-release formulation
• SGLT2 inhibitors are contraindicated due to recurrent UTIs or renal impairment
• Sulfonylureas are contraindicated due to hypoglycemia risk (elderly patients, patients with irregular meal patterns)
• Patient has already failed the step therapy drugs under a previous insurance plan (requires documentation)

The exception request is submitted as part of the PA process. Approval rate for step therapy exceptions is lower than standard PA approval (about 45% vs 65%), because the insurer's default position is that the protocol exists for a reason.

The policy is controversial. The American Diabetes Association's 2024 position statement argues that step therapy for GLP-1 agonists delays optimal treatment and increases long-term complications. Several states (California, New York, Illinois) have passed laws limiting step therapy for chronic disease medications, but enforcement is inconsistent.

If your plan has step therapy and you don't qualify for an exception, the fastest path to Mounjaro is to complete the protocol. Start metformin immediately, document the 90-day trial, then move to step 2. Trying to bypass the protocol without an exception usually results in a PA denial and a longer delay.

Manufacturer copay cards and why they don't work for everyone

Eli Lilly offers a copay savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients. The card covers up to $150 per fill, which makes Mounjaro affordable even on Tier 4.

The card is available at mounjaro.com/savings. Eligibility requirements:

• Commercial insurance (employer-sponsored or ACA marketplace plan)
• Insurance covers Mounjaro (even if on a high tier)
• Not enrolled in a government-funded program (Medicare, Medicaid, VA, TRICARE)
• Prescription is for an FDA-approved indication

The exclusions are significant. About 40% of U.S. adults are covered by government-funded programs and cannot use the card (KFF, 2024 insurance coverage data). For Medicare patients, the card is prohibited by the Anti-Kickback Statute, which treats manufacturer copay assistance as an illegal inducement to use a specific drug.

For commercially insured patients, the card works well but has a catch: the copay card payment does not count toward your deductible or out-of-pocket maximum. If your plan has a $3,000 deductible and you use the copay card for 12 months, you'll pay $25 per month ($300 total), but you'll still have a $3,000 deductible for other medical expenses. The insurer treats the card as if Lilly paid your copay, not you.

Some insurers have "copay accumulator" policies that explicitly exclude manufacturer copay assistance from counting toward the deductible or out-of-pocket max. These policies are legal in most states and are increasingly common. If your plan has a copay accumulator, the card still lowers your monthly cost, but it doesn't move you closer to meeting your deductible.

The card has an annual maximum benefit of $1,800 ($150 per month × 12 months). If your copay exceeds $150 per month (common on Tier 4 plans), you'll pay the difference. For example, if your Tier 4 copay is $450 and you use the card, you'll pay $300 per month ($450 minus $150 card benefit).

The card is valid for 12 months and must be re-enrolled annually. Lilly can discontinue the program at any time, though it's been active since Mounjaro's launch in 2022 and is likely to continue as long as the drug is under patent (expires 2036).

When compounded tirzepatide becomes the more predictable option

Compounded tirzepatide is not covered by insurance. You pay out of pocket. For many patients, this is actually more predictable than navigating insurance tiers, PA requirements, and copay card restrictions.

The cost structure for compounded tirzepatide through FormBlends:

• Initial consultation: $49
• Monthly tirzepatide prescription (2.5 mg to 15 mg, depending on titration): $249 to $399
• No PA required, no step therapy, no formulary changes mid-year

For a patient on a high-deductible plan with Mounjaro on Tier 4, the annual cost comparison:

Brand Mounjaro with insurance (Tier 4, $3,000 deductible, $450 copay after deductible):

• Months 1-2: $1,500 × 2 = $3,000 (paying toward deductible)
• Months 3-12: $450 × 10 = $4,500
• Total: $7,500

Compounded tirzepatide (no insurance):

• Months 1-12: $299 average × 12 = $3,588
• Initial consult: $49
• Total: $3,637

The compounded option costs $3,863 less per year for this patient. Even for a patient with Mounjaro on Tier 3 ($200 copay after deductible), the compounded option is competitive:

Brand Mounjaro (Tier 3, $3,000 deductible, $200 copay after deductible):

• Months 1-2: $1,500 × 2 = $3,000
• Months 3-12: $200 × 10 = $2,000
• Total: $5,000

Compounded tirzepatide: $3,637

The compounded option still saves $1,363 per year.

The trade-off: compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503B compounding pharmacy in response to an individual prescription. The formulation is not identical to brand Mounjaro (different inactive ingredients, different delivery device), and it has not undergone the same manufacturing and quality review process as FDA-approved drugs.

For patients who value cost predictability and immediate access over brand-name assurance, compounded tirzepatide is a rational choice. For patients who prefer FDA-approved products and have insurance that places Mounjaro on Tier 3 with a copay card, brand Mounjaro is more affordable.

The decision depends on your specific insurance situation. If your plan places Mounjaro on Tier 4, requires step therapy, and you don't qualify for the copay card (Medicare, Medicaid, or copay accumulator plan), compounded tirzepatide is often the only financially sustainable option.

The 2026 formulary shift: what's changing

Three trends are reshaping GLP-1 formulary placement in 2026:

1. More plans are moving Mounjaro from Tier 3 to Tier 4.

Novo Nordisk has increased rebates for semaglutide (Ozempic, Wegovy) to defend market share against tirzepatide. Several large PBMs (Express Scripts, CVS Caremark) have responded by moving Mounjaro to Tier 4 and keeping semaglutide on Tier 3. This is a pure price negotiation, not a clinical decision.

The shift affects about 15% of commercially insured patients (roughly 8 million people) who will see their Mounjaro copay increase by $150 to $300 per month starting January 2026. Patients already on Mounjaro are usually grandfathered at the old tier for the remainder of the plan year, but new starts go directly to Tier 4.

2. More plans are adding quantity limits.

Some plans now limit Mounjaro to one pen per 28 days (four pens per 112 days) to prevent stockpiling during the ongoing tirzepatide shortage. The limit is enforced at the pharmacy: if you try to refill early, the claim rejects. The limit applies regardless of tier placement.

The quantity limit creates a problem for patients who need to travel or who want a backup supply. The workaround: ask your provider to write the prescription for a 90-day supply (12 pens) and submit a quantity limit exception to the insurer. Approval rate is about 70% if the provider documents a specific reason (international travel, natural disaster preparedness, previous supply chain interruption).

3. More plans are covering weight-loss indications (but with higher tiers).

As of January 2026, 62% of large employers cover GLP-1 medications for weight loss, up from 41% in 2024 (Business Group on Health, 2025 survey). The coverage is typically on Tier 4 with strict PA criteria (BMI ≥ 30, documented 6-month weight-loss attempt, no contraindications).

The expansion is driven by clinical data showing GLP-1s reduce cardiovascular events in patients with obesity (SELECT trial, Lincoff et al., NEJM 2023). Employers are calculating that covering GLP-1s for weight loss reduces long-term medical costs (fewer heart attacks, strokes, joint replacements). The tier placement is high to control short-term costs, but coverage is expanding.

The net effect: Mounjaro is becoming more expensive through insurance for many patients (Tier 4 placement, quantity limits), but more patients have at least some coverage (weight-loss indication now covered by more plans). The trend favors patients with low-deductible plans and penalizes patients with high-deductible plans.

FAQ

What tier is Mounjaro on most insurance plans? Mounjaro typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the insurer. Tier 3 copays average $150 to $300 per month after deductible. Tier 4 copays average $400 to $600 per month. About 60% of commercial plans place it on Tier 3 as of 2026.

Does Medicare cover Mounjaro? Medicare Part D covers Mounjaro only for type 2 diabetes, not for weight loss. Federal law prohibits Part D from covering weight-loss medications. If you have diabetes, Mounjaro is typically on Tier 3 or Tier 4 with prior authorization required. If you don't have diabetes, Medicare will not cover it.

Why is Mounjaro on a higher tier than metformin? Metformin is a generic drug (Tier 1) that costs insurers about $4 per month. Mounjaro is a brand-name biologic that costs insurers about $900 per month after rebates. Insurers use tier placement to steer patients toward cheaper drugs first. Higher tier means higher cost to the insurer.

Can I use a Mounjaro copay card if I have Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare, Medicaid, VA, and TRICARE beneficiaries. The copay card is available only for patients with commercial insurance. If you have Medicare, you pay the full Tier 3 or Tier 4 copay.

What's the difference between Tier 3 and Tier 4 for Mounjaro? Tier 3 is "preferred brand" and typically has a copay of $150 to $300 per month after deductible. Tier 4 is "non-preferred brand" and typically has a copay of $400 to $600 per month. The difference is about $200 to $300 per month, or $2,400 to $3,600 per year.

How do I find out what tier Mounjaro is on my plan? Log into your insurance member portal and search for "Mounjaro" in the drug lookup tool. Or download your plan's formulary PDF (usually under "Plan Documents"). Or call member services and ask directly. Your pharmacy can also look it up when you bring in a prescription.

Does prior authorization change the tier? No. Prior authorization is separate from tier placement. The tier determines your copay amount. Prior authorization determines whether the insurer will cover the drug at all. Most plans require both: Mounjaro is on Tier 3 or 4, and you need PA approval before the pharmacy can fill it.

Is Mounjaro cheaper if I don't use insurance? Rarely. The cash price for Mounjaro is about $1,200 per month. Even on Tier 4 with a $600 copay, insurance is cheaper. The exception: if you use compounded tirzepatide instead of brand Mounjaro, the out-of-pocket cost is $249 to $399 per month, which is often cheaper than insurance for patients on high-deductible plans.

Can my employer change Mounjaro's tier mid-year? Yes, but it's uncommon. Formulary changes typically happen at the start of the plan year (January 1 for most employers). Mid-year changes require 60 days' notice to members. If your copay suddenly increases, check your plan's formulary updates or call member services.

Why do some plans cover Ozempic but not Mounjaro? Formulary placement is based on manufacturer rebates, not clinical superiority. If Novo Nordisk (Ozempic's manufacturer) offered a better rebate than Eli Lilly (Mounjaro's manufacturer), the plan may cover Ozempic on Tier 3 and exclude Mounjaro entirely, or place Mounjaro on Tier 4. It's a business decision.

What happens if I can't afford my Tier 4 copay for Mounjaro? Three options: (1) Use the Mounjaro copay savings card if you have commercial insurance (reduces cost to $25 per month). (2) Ask your provider to submit a formulary exception request to move Mounjaro to Tier 3. (3) Switch to compounded tirzepatide, which costs $249 to $399 per month out of pocket with no insurance.

Does step therapy affect which tier Mounjaro is on? No. Step therapy is a separate requirement that forces you to try cheaper drugs (metformin, then a second oral agent) before the insurer will approve Mounjaro. The tier determines your copay once you're approved. Step therapy determines whether you can access the drug at all. Both are common for Mounjaro.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Pharmaceutical Care Management Association. Formulary Management Survey 2025. PCMA. 2025.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
6. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
7. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs and Formulary Requirements. CMS. 2025.
8. Business Group on Health. Large Employers' 2025 Health Care Strategy and Plan Design Survey. 2025.
9. American Journal of Managed Care. Prior Authorization Approval Rates for Specialty Medications. AJMC. 2024.
10. Social Security Act, Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer. SSA. 1965 (amended 2003).
11. U.S. House of Representatives. Treat and Reduce Obesity Act (H.R. 1577). 118th Congress. 2025.
12. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide vs Placebo. Diabetes Care. 2023.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. ACG. 2022.
14. Kaiser Family Foundation. Health Insurance Coverage of the Total Population. KFF. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of Eli Lilly and Company and Novo Nordisk, respectively. UnitedHealthcare, Anthem, Aetna, Cigna, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.